# A Phase II Clinical Study to Assess the Efficacy and Safety of IBI310 or Placebo Combined With Sintilimab for Advanced Cervical Cancer Subjects Who Have Failed or Cannot Tolerate First-line or Above Platinum-based Chemotherapy

> **NCT04590599** · PHASE2 · COMPLETED · sponsor: **Innovent Biologics (Suzhou) Co. Ltd.** · enrollment: 205 (actual)

## Conditions studied

- Advanced Cervical Cancer

## Interventions

- **DRUG:** IBI310
- **DRUG:** Placebo
- **DRUG:** Sintilimab

## Key facts

- **NCT ID:** NCT04590599
- **Lead sponsor:** Innovent Biologics (Suzhou) Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-12-08
- **Primary completion:** 2023-11-20
- **Final completion:** 2023-11-20
- **Target enrollment:** 205 (ACTUAL)
- **Last updated:** 2023-12-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04590599

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04590599, "A Phase II Clinical Study to Assess the Efficacy and Safety of IBI310 or Placebo Combined With Sintilimab for Advanced Cervical Cancer Subjects Who Have Failed or Cannot Tolerate First-line or Above Platinum-based Chemotherapy". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT04590599. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*